In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to ...

Positive Feedback on Phase III Trial Design LONDON, Feb. 5, 2025 /PRNewswire/ -- Serac Healthcare Limited (Serac Healthcare ...

Drug addiction is a condition in which there is uncontrolled use of a substance with a harmful outcome. Drugs overstimulate the brain’s reward circuit, producing pleasure or euphoria. With repeated ...

Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...

Drug-resistant infections occur when pathogens change in ways that render antimicrobial drugs ineffective. As a result, the pathogens survive and continue to spread. When infections are treatable with ...

Telix Pharma completes acquisition of next-generation therapeutic assets & innovative biologics technology platform of ImaginAb: Melbourne, Australia Saturday, February 1, 2025, 1 ...

Oxide nanoparticles, particularly iron oxide, ceria and silica nanoparticles, hold significant promise for biomedical applications owing to their unique magnetic, catalytic and porous properties ...

Drug development describes the process of developing a new drug that effectively targets a specific weakness in a cell. This process involves specific pre-clinical development and testing ...

Consisting of five separate booklets, the World Drug Report 2022 provides an in-depth analysis of global drug markets and examines the nexus between drugs and the environment within the bigger picture ...

MELBOURNE - Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX), a pharmaceutical company with a market capitalization of $6 billion and impressive revenue growth of 81% over the last twelve months, ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from ...